Skip to content

Safety, Tolerability and Sensory evaluation of HTUL-031908

An Openââ?¬â??Label Clinical study to evaluate the Safety, Tolerability and Sensory evaluation of HTUL-031908 in Healthy Adult Volunteers

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/041874
Enrollment
12
Registered
2022-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Himalaya Wellness Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Each subject must meet all the following criteria to be enrolled in this study: 1) Adult volunteers of either sex with good health. 2) Aged between �18 to � 60 years. 3) Subjects willing to sign informed consent and follow the study procedure and instructions. 4) Has not participated in a similar investigation in the past four weeks. 5) Women in reproductive age group who will agree to follow an acceptable contraceptive method.

Exclusion criteria

Exclusion criteria: Subjects meeting any of the following criteria will be excluded from the study: 1) Subjects with clinically significant cardiovascular, cerebrovascular, respiratory, liver, renal disease, congenital or any other systemic condition requiring therapeutic intervention. 2) A known history or present condition of allergic response to pharmaceutical products its components or ingredients in the test products. 3) Pre-existing systemic disease necessitating long-term medications. 4) Genetic and endocrinal disorders. 5) Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
1. To assess the safety of HTUL-031908 with number of adverse events observed or reported during the study period in healthy adult volunteers 2. To assess the tolerability and sensory evaluation of HTUL-031908 with total compliance to the study intervention Timepoint: �Visit 1 Screening/-1 week �Visit 2 Day1/ screening �Visit 3 Day 8/ End of study

Secondary

MeasureTime frame
Not applicableTimepoint: Not applicable

Countries

India

Contacts

Public ContactDr Soorya Narayan H

Himalaya Wellness Company

dr.swathi.b@himalayawellness.com8067547232

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026